Pre‐treatment comorbidities, C‐reactive protein and eosinophil count, and immune‐related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entities

BACKGROUND: The development of immune‐related adverse events (irAEs) may be associated with clinical efficacy of checkpoint inhibitors (CPIs) in patients with cancer. We therefore investigated the effect of irAEs and pre‐treatment parameters on outcome in a large, real‐life patient cohort. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehra, Tarun, Dongre, Kanchan, Boesing, Maria, Frei, Patricia, Suenderhauf, Claudia, Zippelius, Alfred, Leuppi, Joerg D., Wicki, Andreas, Leuppi‐Taegtmeyer, Anne B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278511/
https://www.ncbi.nlm.nih.gov/pubmed/37084178
http://dx.doi.org/10.1002/cam4.5919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278511/
https://www.ncbi.nlm.nih.gov/pubmed/37084178
http://dx.doi.org/10.1002/cam4.5919

Ejemplares similares